so the generics launch while the appeal is pending? They spend the capital to launch a drug not knowing the outcome. A drug with lower than average margins that will do a 600 million that will be split between Amarin and a bunch of generics. I dont pretend to understand the economics but it doesnt seem like there is alot of money to be made at this point in the growth cycle